Replies to post #41087 on Biotech Values

[spartex]

RPRX

<I think it is reasonable--in terms of market cap--for this to be a $250-$350 M stock this year. However, in terms of multiples of current PPS, even this is an ambitious target.

With the stock offering (dilution), at the current price of around $13.2, the market cap will equal ~ 168 M.

According to your "reasonable" market cap for this year that would translate to a $19-27 dollar stock.

So are you saying $19-27 range is "an ambitious target" or are you talking more of a stock price in the $30++ range?

Regarding attending the event. If you had the spare time, I guess it would just be useful to see how their story is being communicated and the interest by the investors. Other than that, yeah, I understand your sentiment.

Thanks!

[ThomasS]

RPRX: Pricing IS Tuesday night:

Repros Therapeutics Inc (RPRX)
Secondary $rprx 2.5M CIBC & PUNK, THNK (week of 01/29/07) Tuesday night

[Dr Bill]

RE rfk1862/RPRX - I'm a little more exhuberant than that!

You're only looking for slightly more than double, on the high side?

Look at AMAG- went from 10-65 in just over a year, and doesn't have nearly the potential of this blockbuster.

There is currently not one good answer to women suffering with Fibroids. Ditto Endometriosis. Sales are easily 1.5 B worldwide. Give it a small multiple of 5 and divide by 12.8 Million shares and add in 60 Million dollars to boot - my previous example of europe androxal being worth an upfront cash of 30 million plus 30 million from the offering.

Plus phizer bayer etc pipelines, are all hurting right now, and probably are taking a very strong look at this one.